Non-transplant surgical therapy options of heart failure

Minerva Cardioangiologica

Volumn 62, Issue 6, 2014, Pages 481-496

  Neragi Miandoab, S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Heart failure; Operative; Surgical procedures; Transplantation

Indexed keywords

AORTA STENOSIS; AORTA VALVE REPLACEMENT; BLOOD PUMP; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPLASTY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR THERAPEUTIC DEVICE; CONGESTIVE HEART FAILURE; FALSE ANEURYSM; HEART ARRHYTHMIA; HEART MUSCLE REVASCULARIZATION; HEART VENTRICLE REMODELING; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MITRAL VALVE DISEASE; MITRAL VALVE REPAIR; MITRAL VALVE REPLACEMENT; REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; ARTIFICIAL HEART; DISEASE COURSE; HEART ASSIST DEVICE; HEART FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA;

DISEASE PROGRESSION; HEART FAILURE; HEART TRANSPLANTATION; HEART, ARTIFICIAL; HEART-ASSIST DEVICES; HOSPITALIZATION; HUMANS; VENTRICULAR REMODELING;

EID: 84926200715     PISSN: 00264725     EISSN: 18271618     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Neragi-Miandoab S. Zur Bedeutung der Therapie mit ACE-Hemmern bei experimenteller Herzinsuffizienz. In: Breisgau A-L-UFi, editor. Freiburg, Germany: Al-bert-Ludwigs-Universitat Freiburg im Breisgau; 1999. p. 46.
2. Benetis R. Surgical treatment of congestive heart failure in coronary artery disease. Roczniki Akademii Medycznej w Bialymstoku 2005;50:45-9
3. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K et al. American Heart Association Statistics C, Stroke Statistics S: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-171.
4. Murriel CL, Mochly-Rosen D. Opposing roles of delta and epsilonPKC in cardiac ischemia and reper-fusion: targeting the apoptotic machinery. Arch Bio-chem Biophys 2003;420:246-54.
5. Ohuchi H, Madsen JC, Neragi-Miandoab S, Vlahakes GJ. A novel technique for en bloc, vascularized, composite thymic, and cardiac co-transplantationl. Transplantation 2002;74:403-5.
6. Hunt SA. Current status of cardiac transplantation. JAMA 1998;280:1692-8.
7. Tavazzi L. Epidemiology of dilated cardiomyopathy: a still undetermined entity. Eur Heart J 1997;18:4-6.
8. Neragi-Miandoab S. A ventricular assist device as a bridge to recovery, decision making, or transplantation in patients with advanced cardiac failure. Surgery Today 2012;42:917-26.
9. Goldstein D, Neragi-Miandoab S. Mechanical bridge to decision: what are the options for the management of acute refractory cardiogenic shock? Curr Heart Fail Rep 2011, 8:51-8.
10. Neragi-Miandoab S, Goldstein D, Bello R, Michler R, D'Alessandro D. Right ventricular dysfunction following continuous flow left ventricular assist device placement in 51 patients: predicators and outcomes. J Cardiothor Surg 2012;7:60.
11. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG. American College of C, American Heart Association Task Force on Practice G, American College of Chest P, International Society for H, Lung T, Heart Rhythm S: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
12. Wang F, Guan J. Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy. Adv Drug Deliv Rev 2010;62:784-97.
13. Akhmedov AT, Marin-Garcia J. Myocardial regeneration of the failing heart. Heart Fail Rev 2013;18:815-33.
14. Neragi-Miandoab S, Vlahakes GJ. Elevated troponin I level with hemoglobin based oxygen carrying solutions (HBOCs) as a priming solution despite improved left ventricular function. Interact Cardiovasc Thorac Surg 2006;5:135-8.
15. Wilkoff BL, Kudenchuk PJ, Buxton AE, Sharma A, Cook JR, Bhandari AK et al. The DAVID (Dual Chamber and WI Implantable Defibrillator) II trial. J Am Coll Cardiol 2009;53:872-80.
16. Rizzello V, Poldermans D, Schinkel AF, Biagini E, Boersma E, Elhendy A. Outcome after redo coronary artery bypass grafting in patients with ischae-mic cardiomyopathy and viable myocardium. Heart 2007;93:221-5.
17. Buszman P, Szkrobka I, Gruszka A, Parma R, Tendera Z, Lesko B. Comparison of effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in patients with ischemic cardiomyopathy. Am J Cardiol 2007;99:36-41.
18. Peovska I, Maksimovic J, Vavlukis M, Davceva J, Pop Gorceva D, Majstorov V. Relationship between myocardial viability and improvement in left ventricular function and heart failure symptoms after coronary artery bypass surgery, Prilozi/Makedon-ska akademija na naukite i umetnostite, Oddelenie za bioloski i medicinski nauki = Contributions/Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences 2007;28:97-112.
19. Senior R, Kaul S, Lahiri A. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure. J Am Coll of Cardiol 1999;33:1848-54.
20. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992, 20:1594-8.
21. Radovanovic N, Mihajlovic B, Selestiansky J, Torbica V, Mijatov M, Popov M. Reductive annuloplasty of double orifices in patients with primary dilated cardiomyopathy, The Ann Thorac Surg 2002;73:751-5.
22. Calafiore AM, Mauro MD, Gallina S, Yassin IM, Shaheen YA, Canosa C. Surgical Treatment of Mitral Valve Regurgitation in Dilated Cardiomyopathy. Heart Surg Forum 2004;7:21-5.
23. Spoor MT, Geltz A, Boiling SF. Flexible versus non-flexible mitral valve rings for congestive heart failure: differential durability of repair. Circulation 2006;114:167-71.
24. De Bonis M, Ferrara D, Taramasso M, Calabrese MC, Verzini A, Buzzatti N et al. Mitral replacement or repair for functional mitral regurgitation in dilated and ischemic cardiomyopathy: is it really the same? Ann Thorac Surg 2012;94:44-51.
25. Ngaage DL, Daly RC, Rosales G, Sundt TM, 3rd, Dearani JA, Mullany CJ et al. Mitral regurgitation surgery in heart failure due to ischemic cardiomyopathy: a 24-year experience. J Heart Valve Dis 2008;17:251-9; discussion 259-260.
26. Neragi-Miandoab S. Management of bicuspid aortic valve with or without involvement of ascending aorta and aortic root. J Cardiovasc Surg 2014;55:435-44.
27. Poulsen SH, Sogaard P, Nielsen-Kudsk JE, Egeblad H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. J Am Soc Echocardiography 2007;20:877-84.
28. Zile MR, Gaasch WH. Heart failure in aortic stenosis - improving diagnosis and treatment. New Engl J Med 2003;348:1735-6.
29. Zakrzewski D, Orlowska-Baranowska E, Sitko T, Religa G, Hoffman P et al. Early and long-term outcomes after surgical treatment in patients with aortic stenosis and severe left ventricular heart failure without concomitant coronary artery disease with respect to preoperative mean transvalvular pressure gradient. Kardiologia polska 2007;65:153-7; discussion 158-159.
30. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. New Engl J Med 2011;364:2187-98.
31. Neragi-Miandoab S, Salemi A. The most relevant complications of transcatheter aortic valve implantation according to VARC criteria. Minerva Cardioan-giol 2014;62:205-20.
32. Neragi-Miandoab S, Skripochnik E, Michler RE. Recently patented and widely used valves for transcatheter aortic valve implantation. Recent Pat Car-diovasc Drug Discov 2012;7:196-205.
33. Neragi-Miandoab S, Skripochnik E, Salemi A, Girardi L. Recently patented transcatheter aortic valves in clinical trials. Recent Pat Cardiovasc Drug Discov 2013;8:186-91.
34. Neragi-Miandoab S, Mohr FW, Borger MA, Holzhey DM. Transapical implantation of an Edwards Sapien valve into a failed prosthetic mitral valve 3 years after a transapical aortic valve implantation. J Thorac Cardiovasc Surg 2013; l45:e19-21.
35. Eggebrecht H, Schafer U, Treede H, Boekstegers P, Babin-Ebell J, Ferrari M et al. Valve-in-valve transcatheter aortic valve implantation for degenerated bioprosthetic heart valves, JACC Cardiovasc Interv 2011;4:1218-27.
36. Wenger NK. Oral anticoagulant therapy at elderly age. Heart failure and nonvalvular atrial fibrillation. Am J Geriatr Cardiol 1996;5:78-83.
37. Gerber TC, Nishimura RA, Holmes DR, Jr., Lloyd MA, Zehr KJ, Tajik AJ et al. Left ventricular and biventricular pacing in congestive heart failure. Mayo Clin Proc 2001;76:803-12.
38. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW et al. Gender differences in advanced heart failure: insights from the BEST study, J Am Coll Cardiol 2003;42:2128-34.
39. Baldasseroni S, Opasich C, Gorini M, Lucci D, Marchionni N, Marini M et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002;143:398-405.
40. Auricchio A, Abraham WT. Cardiac resynchroniza-tion therapy: current state of the art: cost versus benefit. Circulation 2004;109:300-7.
41. Turner MS, Bleasdale RA, Vinereanu D, Mumford CE, Paul V, Fraser AG et al. Electrical and mechanical components of dyssynchrony in heart failure patients with normal QRS duration and left bundle-branch block: impact of left and biventricular pacing, Circulation 2004;109:2544-9.
42. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Sudden Cardiac Death in Heart Failure Trial I: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
43. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E et al. Cardiac resynchronization in chronic heart failure. New Engl J Med 2002;346:1845-53.
44. Saxon LA, Ellenbogen KA. Resynchronization therapy for the treatment of heart failure, Circulation 2003;108:1044-8.
45. Navia JL, Atik FA, Grimm RA, Garcia M, Vega PR, Myhre U et al. Minimally invasive left ventricular epi-cardial lead placement: surgical techniques for heart failure resynchronization therapy. Ann Thorac Surg 2005;79:1536-44; discussion 1536-1544.
46. Sundell J, Engblom E, Koistinen J, Ylitalo A, Naum A, Stolen KQ et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics, and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol 2004;43:1027-33.
47. Zhang Q, Fung JW, Auricchio A, Chan JY, Kum LC, Wu LW et al. Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure. Eur Heart J 2006;27:1423-30.
48. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. Cardiac Resynchroni-zation-Heart Failure Study I: The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med 2005;352:1539-49.
49. Strickberger SA, Conti J, Daoud EG, Havranek E, Mehra MR, Pina IL et al. Council on Clinical Cardiology Subcommittee on E, Arrhythmias, the Quality of C, Outcomes Research Interdisciplinary Working G, Heart Rhythm S: Patient selection for cardiac resynchronization therapy: from the Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation 2005;111:2146-50.
50. Tang AS, Ross H, Simpson CS, Mitchell LB, Dorian P, Goeree R et al. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol 2005;21(Suppl A):11A-18A.
51. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L et al. Treatment of Chronic Heart Failure of the European Society of C: Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
52. Daubert JC, Ritter P, Le Breton H, Gras D, Leclercq C, Lazarus A et al. Permanent left ventricular pacing with transvenous leads inserted into the coronary veins. Pacing Clin Electrophysiol 1998;21:239-45.
53. Kass DA. Pathobiology of cardiac dyssynchrony and resynchronization. Heart Rhythm 2009;6:1660-5.
54. Cleland J, Tageldien A, Khaleva O, Hobson N, Clark AL. Should patients who have persistent severe symptoms receive a left ventricular assist device or cardiac resynchronization therapy as the next step? Heart Fail Clin 2007;3:267-73.
55. Liang YJ, Zhang Q, Fung JW, Chan JY, Yip GW, Lam YY et al. Impact of reduction in early- and late-systolic functional mitral regurgitation on reverse remodelling after cardiac resynchronization therapy. Eur Heart J 2010;31:2359-68.
56. Boriani G, Gasparini M, Landolina M, Lunati M, Biffi M, Santini M et al. Impact of mitral regurgitation on the outcome of patients treated with CRT-D: data from the InSync ICD Italian Registry. Pacing Clin Electrophysiol 2012;35:146-54.
57. Upadhyay GA, Choudhry NK, Auricchio A, Ruskin J, Singh JP. Cardiac resynchronization in patients with atrial fibrillation: a meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008;52:1239-46.
58. Batista R. Partial left ventriculectomy-the Batista procedure. Eur J Cardiothorac Surg 1999;15(Suppl 1):S12-19; discussion S39-43.
59. O'Neill JO, Starling RC, McCarthy PM, Albert NM, Lytle BW, Navia J et al. The impact of left ventricular reconstruction on survival in patients with ischemic cardiomyopathy. Eur J Cardiothorac Surg 2006;30:753-9.
60. Mickleborough LL, Carson S, Ivanov J. Repair of dys-kinetic or akinetic left ventricular aneurysm: results obtained with a modified linear closure. J Thorac Cardiovasc Surg 2001;121:675-82.
61. Dor V, Sabatier M, Di Donato M, Montiglio F, Toso A, Maioli M. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998;116:50-9.
62. Nair RU, Barker D, Kumar S, Javengula K, Tan LB. Medium-term results of surgical ventricular restoration with papillary muscle realignment: providing additional benefits in enlarged ischemic left ventricle. Surg Technol Int 2008;17:222-6.
63. Batista RJ, Verde J, Nery P, Bocchino L, Takeshita N, Bhayana JN et al. Partial left ventriculectomy to treat end-stage heart disease. Ann Thorac Surg 1997;64:634-8.
64. McCarthy JF, McCarthy PM, Starling RC, Smedira NG, Scalia GM, Wong J et al. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardiothorac Surg 1998;13:337-43.
65. Camero-Alcazar M, Alswies A, Perez-Isla L, Silva-Guisasola JA, Gonzalez-Ferrer JJ, Reguillo-Lacruz F et al. Short-term and mid-term follow-up of sutureless surgery for postinfarction subacute free wall rupture. Interact Cardiovasc Thorac Surg 2009;8:619-23.
66. Frances C, Romero A, Grady D. Left ventricular pseudoaneurysm. J Am Coll Cardiol 1998;32:557-61
67. Kupari M, Verkkala K, Maamies T, Hartel G. Value of combined cross sectional and Doppler echocardiography in the detection of left ventricular pseudoaneurysm after mitral valve replacement. Br Heart J 1987;58:52-6.
68. Konen E, Merchant N, Gutierrez C, Provost Y, Mickleborough L, Paul NS et al. True versus false left ventricular aneurysm: differentiation with MR imaging-initial experience. Radiology 2005;236:65-70.
69. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617-25.
70. Eren E, Bozbuga N, Toker ME, Keles C, Rabus MB, Yildirim O et al. Surgical treatment of post-infarction left ventricular pseudoaneurysm: a two-decade experience, Texas Heart Institute journal/from the Texas Heart Institute of St Luke's Episcopal Hospital. Texas Children's Hospital 2007;34:47-51.
71. Tasdemir O, Kucukaksu SD, Vural KM, Katircioglu FS, Kutuk E, Bayazit K. A.comparison of the early and midterm results after dynamic cardiomyoplasty in patients with ischemic or idiopathic cardiomyopathy. J Thorac Cardiovasc Surg 1997;113:173-80; discussion 180-171.
72. Oh JH, Badhwar V, Mott BD, Li CM, Chiu RC. The effects of prosthetic cardiac binding and adynamic cardiomyoplasty in a model of dilated cardiomyopathy. J Thorac Cardiovasc Surg 1998;116:148-53.
73. Speziale G, Nasso G, Piancone F, Generali K, Paterno C, Miccoli A et al. One-year results after implantation of the CorCap for dilated cardiomyopathy and heart failure. Ann Thorac Surg 2011;91:1356-62.
74. Power JM, Raman J, Dornom A, Farish SJ, Burrell LM, Tonkin AM et al. Passive ventricular constraint amends the course of heart failure: a study in an ovine model of dilated cardiomyopathy. Cardiovasc Res 1999;44:549-55.
75. Starling RC, Jessup M, Oh JK, Sabbah HN, Acker MA, Mann DL et al. Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: three year follow-up results from the Acorn clinical trial. Ann Thorac Surg 2007;84:1236-42.
76. Mann DL, Acker MA, Jessup M, Sabbah HN, Starling RC, Kubo SH et al. Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg 2007;84:1226-35.
77. Rastogi S, Gupta RC, Mishra S, Morita H, Tanhehco EJ, Sabbah HN. Long-term therapy with the acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. J Heart Lung Transplant 2005;24:1619-25.
78. Chaudhry PA, Mishima T, Sharov VG, Hawkins J, Alfemess C, Paone G et al. Passive epicardial containment prevents ventricular remodeling in heart failure. Ann Thorac Surg 2000;70:1275-80.
79. Shafy A, Fink T, Zachar V, Lila N, Carpentier A, Chachques JC. Development of cardiac support bio-prostheses for ventricular restoration and myocardial regeneration. Eur J Cardiothorac Surg 2013;43:1211-9.
80. Acker MA, Jessup M, Boiling SF, Oh J, Starling RC, Mann DL et al. Mitral valve repair in heart failure: five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. J Thorac Cardiovasc Surg 2011;142:569-74, 574 e561.
81. Mann DL, Kubo SH, Sabbah HN, Starling RC, Jessup M, Oh JK et al. Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg 2012, 143:1036-42.
82. Sabbah HN. The cardiac support device and the myosplint: treating heart failure by targeting left ventricular size and shape. Ann Thorac Surg 2003;75:S13-19.
83. Hamner C, Ruth G, Raffe M, Schoen FJ, Schaff H. Safety and biocompatibility of the Myosplint system-a passive implantable device that alters ventricular geometry for the treatment of heart failure. ASAIO J 2004;50:438-43.
84. Fukamachi K, McCarthy PM. Initial safety and feasibility clinical trial of the myosplint device. J Cardiac Surg 2005;20:S43-47.
85. Guccione JM, Salahieh A, Moonly SM, Kortsmit J, Wallace AW, Ratcliffe MB. Myosplint decreases wall stress without depressing function in the failing heart: a finite element model study. Ann Thorac Surg 2003;76:1171-80; discussion 1180.
86. McCarthy PM, Takagaki M, Ochiai Y, Young JB, Tabata T, Shiota T et al. Device-based change in left ventricular shape: a new concept for the treatment of dilated cardiomyopathy, J Thorac Cardiovasc Surg 2001;122:482-90.
87. John R, Pagani FD, Naka Y, Boyle A, Conte JV, Russell SD et al. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. J Thorac Cardiovasc Surg 2010;140:174-81.
88. John R, Liao K, Lietz K, Kamdar F, Colvin-Adams M, Boyle A et al. Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure, J Thorac Car-diovasc Surg 2007;134:351-8.
89. Neragi-Miandoab S. A ventricular assist device as a bridge to recovery, decision making, or transplantation in patients with advanced cardiac failure. Surg Today 2012.
90. Neragi-Miandoab S, Goldstein D, Bello R, Michler R, D'Alessandro D. Right ventricular dysfunction following continuous flow left ventriccular assist device placement in 51 patients: predicators and outcomes. J Cardiothorac Surg 2012;7:60.
91. Neragi-Miandoab S, Goldstein D, D'Alessandro DA. TandemHeart Device as Rescue Therapy in the Management of Acute Heart Failure. Heart Surg Forum 2014;17:E160-162.
92. Smedira NG, Hoercher KJ, Yoon DY, Rajeswaran J, Klingman L, Starling RC et al. Bridge to transplant experience: factors influencing survival to and after cardiac transplant. J Thorac Cardiovasc Surg 2010;139:1295-305, 1305 e1291-1294.
93. Kovacic JC, Nguyen HT, Karajgikar R, Sharma SK, Kini AS. The Impella Recover 2.5 and TandemHeart ventricular assist devices are safe and associated with equivalent clinical outcomes in patients undergoing high-risk percutaneous coronary intervention. Catheter Cardiovasc Interv 2013;82:E28-37.
94. Vranckx P, Meliga E, De Jaegere PP, Van Den Ent M, Regar ES, Serruys PW. The TandemHeart, percutaneous transseptal left ventricular assist device: a safeguard in high-risk percutaneous coronary interventions. The six-year Rotterdam experience. Eu-rolntervention 2008;4:331-7.
95. Dimas W, Murthy R, Guleserian KJ. Utilization of the Impella 2.5 micro-axial pump in children for acute circulatory support. Catheter Cardiovasc Interv 2014;83:261-2.
96. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ et al. HeartMate III: Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-21.
97. Wu L, Weng YG, Dong NG, Krabatsch T, Stepanenko A, Hennig E et al. Outcomes of HeartWare Ventricular Assist System support in 141 patients: a single-centre experience, European journal of cardio-thoracic surgery: official journal of the European Association for Cardiothorac Surg 2013;44:139-45.
98. Wieselthaler GM, GOD, Jansz P, Khaghani A, Strueber M, Investigators HC. Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial. J Heart Lung Transpl 2010;29:1218-25.
99. Strueber M, Larbalestier R, Jansz P, Zimpfer D, Fiane AE, Tsui S et al. Results of the post-market Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE). J Heart Lung Transplant 2014;33:486-91.
100. John R, Long JW, Massey HT, Griffith BP, Sun BC, Tector AJ et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 2011;141:932-9.